Abstract
Repeated exposures to Saccharopolyspora rectivirgula in some individuals can lead to a hypersensitivity reaction where a pro-inflammatory feedback loop can occur in the interstitial space in the alveoli of the lungs that can ultimately lead to granuloma formation and fibrosis, referred to as Hypersensitivity pneumonitis or Farmer’s Lung Disease. The pathogenesis of FLD is complex and incompletely understood. S. rectivirgula induces an immune response, triggering neutrophil influx into the lung followed by lymphocyte influx of CD8+ and CD4+ T cells. The cytokine IL17A has been shown to be critical for the development of S. rectivirgula induced Hypersensitivity pneumonitis. This chapter will review the immune response leading to the development of S. rectivirgula induced Hypersensitivity pneumonitis.
Keywords
- Saccharopolyspora rectivirgula
- hypersensitivity pneumonitis
- farmer’s lung disease
- lung inflammation
- immune response
1. Introduction
Bacteria were one of the very first organisms to inhabit the Earth three billion years ago [1, 2]. Using today’s current technological approaches to determine the total mass of all the organisms on Earth, would reveal that bacteria are second most dominant organism on the planet [3]. Bacteria are important for human health, providing nutrients, protecting against developing diseases, aiding in food production, energy storage, helping to train the immune system and have the potential to capture carbon dioxide to reduce greenhouse gas emissions [4]. One of the most important discoveries of bacteria is that they can make antibiotics to treat bacterial diseases. The discovery of novel bacteria was prominent throughout the 1920’s until the 1970’s where the antibiotic resistant diseases were starting to take a foothold in the world [5, 6]. The discovery of new bacteria that have the potential to alleviate antimicrobial resistance is still an issue today. The phylum
1.1 History of Saccharopolyspora and its isolation
The genus
1.2 Hypersensitivity pneumonitis (HP) or farmer’s lung disease (FLD)
HP was first described by Bernardino Ramazzini da Capri in the early 1700s when he encountered workers that sifted grain developed a dry cough coupled with edema and weight loss [21]. He suggested the workers developed the cough due to the humid environments inside the wheat dust [21]. In the early 1930s farmer’s lung disease was first described by John Campbell after seeing five patients whom had pulmonary difficulties due to their working conditions [22]. All five patients were farmer laborers working with hay that was improperly stored to keep out moisture. Dr. Campbell obtained samples of “dust” from the hay and discovered fungi present. However, he was unable to discover the origin of disease, and found no correlation with the presence of fungi and his patients’ sputum samples. Today, we know HP as a collection of lung diseases that can occur in an occupational, recreational or home settings. HP is caused by the repeated exposure to organic or inorganic agents such as avian proteins, chemicals, molds, and bacteria, among others where the subset of HP is categorized by the offending agent [19, 20, 23]. Individuals are asymptomatic or symptomatic leading to a hypersensitive reaction. Historically, HP has been characterized into three stages, acute, sub-acute and chronic but the field seems to be moving towards categorizing HP in a sensitization phase and challenge phase [24]. The onset of symptoms are fever, cough, wheezing, chills and if left untreated patients can experience dyspnea, fatigue, weight loss and fibrosis [23]. Some individuals develop poorly formed granulomas that advance to pulmonary fibrosis [25, 26, 27, 28], which can lead to irreversible dysfunction with an increase in mortality [29], and some patients may even develop emphysema [30, 31]. Early diagnosis and treatment of HP and farmer’s lung disease may prevent long term effects. However, HP is difficult to diagnose due to patients’ symptoms that have similar pathologies to other respiratory diseases such as asthma or idiopathic pulmonary fibrosis coupled with a lack of a standardized diagnostic testing [23, 26, 32].
Diagnosis of patients with HP including farmer’s lung disease is a multi-factorial process. A clinical history is taken to determine the patients’ symptoms, descriptions of the environment they interact with such as work and home [33]. Samples from the patients’ environment may be undertaken to undergo microbiological identification. When an offending agent is unknown, in some cases diagnosis would include provoking a physiological response from the patient by conducting an inhalation challenge with various potential triggers to try to determine the nature of the offending agent [19, 33, 34, 35, 36]. Serum antibody tests are used to determine if the patient has been sensitized to the offending agent. IgG has been shown to be associated with farmer’s lung patients that develop symptoms or those that asymptomatic [19, 33]. A standardized enzyme-linked immunosorbent assay (ELISA) test has yet to be developed and adapted in the clinical setting or able to differentiate between patients who have been exposed from those that have actual manifestation of the disease [23, 37]. Sputum or serum samples may be collected to determine lymphocytosis or alveolitis in bronchial lavage fluid (BAL) [33]. High resolution CT of the chest or bronchoscopy may be used to differentiate FLD from other diseases that have similar clinical features [19, 33]. Lung biopsy is reserved for patients where there has been no identification of the specific antigen exposure [37].
Treatment options are limited for all subsets of HP. The best treatment for patients is to avoid the offending antigen or utilize personal protective equipment. Determining the offending agent can be challenging and avoiding it may not be feasible for resolution for all [23, 38]. Personal protective equipment is successful in reducing inhalation of antigens but might be financially challenging or have low compliance rates [38]. Even in the cases of FLD, improvement of hay packing techniques meant to reduce bacterial or fungi growth do not always work [39, 40]. Furthermore, in some cases when avoidance of the offending agent is successful some patients may still have a decline in lung function [23, 35]. Corticosteroids may be prescribed for certain patient demographics as they reduce the immune response but is not beneficial for long term usage [41].
Farmer’s lung affects approximately up to 20 percent of individuals that typically work in agricultural settings (i.e. dairy farms) where environmental and genetic factors influence the susceptibility of workers, and even in some cases that of their families [23, 27, 35, 42, 43, 44]. However, not all exposed individuals develop FLD suggesting a genetic component that lead to developing symptoms [42]. The environmental factors and genetic factors that contribute to the development of FLD remains incompletely understood.
1.3 Environmental impact of FLD
Secondary infections, pesticides, air quality, among others have all been attributed to increased susceptibility to developing HP including FLD [45, 46, 47]. Interestingly, smokers have a decreased risk of developing HP but non-smokers have a lower risk of developing emphysema [30, 48]. The reduction of risk with smokers developing HP has been attributed to nicotine’s ability to suppress immune responses [48]. There are a variety of antigens that can lead to the development of HP. In some cases, patients are exposed to a mixture of antigens [49, 50, 51]. However, few studies evaluate the immune response when there is a mixture of antigens involved in disease pathogenesis, but there have been some studies looking at co-infection with viruses [46, 51, 52, 53]. For example, in mouse models, Cormier et al., found that single round of infection with Sendai virus following
Our environmental exposure during upbringing impacts our risk of developing allergic diseases whereby increased microbial exposure in early life can reduce the risk of developing allergies or allergic disease in adulthood [54, 55, 56]. The microbiome can modify host-immune responses and dysbiosis of the microbiome can lead to disease [2, 57]. Previous research has shown children that grow up in an agricultural setting have a reduction in developing allergic diseases. Interestingly children have been diagnosed with HP albeit there a very few studies that examine children with HP [58]. Thus, environmental upbringing may not fully explain risk factors to developing FLD. A genetic component may play a role in those with healthy microbiomes that leads to their susceptibility of disease. The microbiome has also been suggested to be able to affect the development of HP including farmer’s lung disease. Russell et al. investigated this effect on the development of FLD using antibiotic-mediated microbial shifts [59]. In experiments where mice were treated prenatally or perinatally with vancomycin or streptomycin and exposed to
1.4 Genetic contribution to FLD
HP including FLD is such a rare disease the studies that genetic analysis of susceptibility to disease are few and far in between. In addition, the majority of studies that have evaluated genetic susceptibility have small sample size in their respective patient cohorts, and do not delineate the causative agent of HP. These reasons, among others, partly explains why there is no consensus on the genetic polymorphisms that may cause individuals to be sensitive to
Polymorphisms in the TNF-α gene have been linked to elevated inflammation, and single nucleotide polymorphisms (SNPs) at −308 position in the promoter region of the TNF gene has been associated with an increased risk to inflammatory diseases. Similarly to TNF-308A, TNF-238G has also been shown to be associated with increased production of plasma TNF-α in systemic lupus erythematous patients [62]. Furthermore, TNF-308A has been shown to be associated with high levels of TNF-α
MHC class I (HLA-DR) and II (HLA-DQ) play a critical role in the adaptive immune response by presenting epitopes from foreign or self-antigens to CD8+ or CD4+ T cells respectively [63]. MHC class I utilizes ATP-binding cassette proteins, transporters associated with antigen processing-1 and 2 (TAP1 and TAP2) to aide in the process of antigen presentation [57]. The genetic regions that encode for MHC are polygenic and incredibly polymorphic, allowing for the recognition of many different epitopes; polymorphism that occur in these gene regions also serve as risk factors in susceptibility to disease [36, 57]. Both TAP1 and TAP2 genes also map within the MHC class II region [64]. Polymorphisms in HLA-DR and DQ have been associated with susceptibility to developing HP, however it is unclear if this association extends to those who develop farmer’s lung [36]. Patients that have HP have been reported to have a significant increase in the frequency of the TAP1 genotypes Asp-637/Gly-637 and Pro-661/Pro-661 among patient cohorts that had bird fancier’s lung compared to healthy controls [64]. Familial studies of HP investigated polymorphisms in MHC class II genes HLA -DRB1/2/3/4/5, -DQA1, -DQB1, -DPA1, -DPB1, -DMA, and -DMB in healthy and HP patients with one patient having been diagnosed with FLD, have found that DRB1*04 alleles and haplotypes could be contributing the susceptibility to HP [65]. This suggests MHC and TAP might have a role in patient susceptibility to disease. However, we do not know if these polymorphisms are only prevalent for those whom may be afflicted with bird fancier’s lung compared to FLD.
Phospholipids and glycoproteins play a large role in maintaining healthy lung function. Dysfunction of these material can increase risk of developing pulmonary diseases. Surfactant is a complex material composed of phospholipids and proteins that reduce the surface tension in the alveoli and bronchiole of fully developed lungs secreted by type II alveolar cells. Pulmonary surfactants, SP-A, SP-B, SP-C and SP-D are critical for normal lung function by maintaining the integrity of alveoli [32, 66]. Surfactants can regulate phagocytosis in alveolar macrophages or bind to pathogens and allergens [67, 68]. The decrease or absence of surfactant that may occur during inflammatory conditions can lead to respiratory failure [32]. There is variability in the levels of surfactant reported in HP [69, 70, 71, 72]. One study found elevated levels of SP-A in patients with farmer’s lung [71]. Surfactants from HP patients have a reduce capacity to inhibit the proliferation of PBMCs [73]. The surfactant protein C gene has been associated with familial interstitial lung diseases.
2. Immune response to S. rectivirgula during development of FLD
The immune response to
Mouse models used have been utilized to study the immune response and pathology of FLD caused by
TLR2 can modulate neutrophil responses [93]. The absence of TLR2 in mice did not affect neutrophil influx in response to a single exposure to
TLRs are not the only way pathogenesis of FLD may occur. Antibodies such as IgG are able to tag
CD4+ T helper cells can fine tune an immune response with their unique abilities to produce a wide variety of cytokines. Naïve CD4+ T cells encounter antigen and can differentiate into T helper (TH) subsets such as TH1, TH2, TH9, TH17, TH22, T follicular cells (TFH), or T regulatory cells (Tregs) and Type 1 regulatory cells (Tr1), depending on signals from the microenvironment. Previous studies were unable to reach a consensus on which TH cell(s) type are important for disease pathogenesis in FLD [28, 74, 76, 85, 86, 97, 98], however, subsequent studies have found a prominent role for TH17 cells. The presence of lung lymphocytes and granuloma formation are classic hallmarks of FLD, and CD4+ and CD8+ T cells are found in the BAL of patients with FLD, suggesting they play a role in pathogenesis [79]. Granuloma formation has been historically associated with macrophages, TH1 and TH2 cells [99, 100]. TH1 cells produce IFN-γ and promote macrophage responses against extracellular or intracellular bacteria [57]. IFN-γ may play an important role since IFN-γ−/− mice (on a Balb/c background) that were exposed to
2.1 Th17 immune response to S. rectivirgula induced FLD
In 2005, a new TH cell type was discovered and determined to be an independent subset from TH1 and TH2 cells [103]. This cell type, the TH17 cell, develops in the presence of TGF-β, IL-1, IL-6, IL-21, or IL-23, and has been shown to protect against extracellular bacteria by producing the pro-inflammatory cytokines IL-17A, IL-17F, and IL-22 [57, 104]. Analysis of gene expression profiles of lung biopsies of patients with HP found an upregulation of the IL-17 receptor IL-17RC, suggesting that TH17 cells may play a role in HP pathogenesis [105]. In a mouse model of
TH17 cells are not the only cell type that can produce IL-17A. Neutrophils, γδ T cells, invariant natural killer cells (iNKT), and group 3 innate lymphoid cells (ILC3s) have all been shown to produce IL-17A [106, 107, 108, 109]. Studies with γδ T cells have shown that they produce IL-17A in
2.2 Anti-inflammatory response during S. rectivirgula induced FLD
The anti-inflammatory responses of
3. Conclusion
It is important to gain a better understanding of rare diseases such as HP. Global climate change caused by human activities are anticipated to affect respiratory diseases with increases in rainy, humid, hot weather which can lead to humid environments which may make environments suitable for the growth of actinobacteria such as
References
- 1.
Panno J. The Cell: Evolution of the First Organism. New York, NY: Infobase Publishing; 2014 - 2.
Wilson BA, Winkler M, Ho BT. Bacterial Pathogenesis: A Molecular Approach. Washington, D.C.: John Wiley & Sons; 2020 - 3.
Bar-On YM, Phillips R, Milo R. The biomass distribution on earth. Proceedings of the National Academy of Sciences. 2018; 115 (25):6506-6511 - 4.
Gleizer S, Ben-Nissan R, Bar-On YM, Antonovsky N, Noor E, Zohar Y, et al. Conversion of Escherichia coli to generate all biomass carbon from CO2. Cell. 2019; 179 (6):1255-1263.e12 - 5.
Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. The Journal of Antibiotics. 2009; 62 (1):5-16 - 6.
Aminov RI. A brief history of the antibiotic era: Lessons learned and challenges for the future. Frontiers in Microbiology. 2010; 1 :134 - 7.
Miao V, Davies J. Actinobacteria: The good, the bad, and the ugly. Antonie Van Leeuwenhoek. 2010; 98 (2):143-150 - 8.
Azman A-S, Othman I, Velu S, Chan K-G, Lee L-H. Mangrove rare actinobacteria: Taxonomy, natural compound, and discovery of bioactivity. Frontiers in Microbiology. 2015; 6 :856 - 9.
Sayed AM, Abdel-Wahab NM, Hassan HM, Abdelmohsen UR. Saccharopolyspora: An underexplored source for bioactive natural products. Journal of Applied Microbiology. 2020; 128 (2):314-329 - 10.
Regal JF, Selgrade M. Hypersensitivity Reactions in the Respiratory Tract. Immune System Toxicology: Elsevier Inc.; 2010. pp. 375-395 - 11.
Lacey J, Goodfellow M. A novel actinomycete from sugar-cane bagasse: Saccharopolyspora hirsuta gen. Et sp. nov. Microbiology. 1975; 88 (1):75-85 - 12.
Korn-Wendisch F, Kempf A, Grund E, Kroppenstedt R, Kutzner H. Transfer of Faenia rectivirgula Kurup and agre 1983 to the genus Saccharopolyspora Lacey and Goodfellow 1975, elevation of Saccharopolyspora hirsuta subsp. taberi Labeda 1987 to species level, and emended description of the genus Saccharopolyspora. International Journal of Systematic and Evolutionary Microbiology. 1989; 39 (4):430-441 - 13.
Lacey J. Thermoactinomyces sacchari sp. nov., a thermophilic actinomycete causing bagassosis. Microbiology. 1971; 66 (3):327-338 - 14.
Lemone DV, Scott WG, Moore S, Koven AL. Bagasse disease of the lungs. Radiology. 1947; 49 (5):556-567 - 15.
Seabury J, Salvaggio J, Buechner H, Kundur V, Bagassois III. Isolation of thermophilic and mesophilic Actinomycetes and fungi from moldy bagasse. Proceedings of the Society for Experimental Biology and Medicine. 1968; 129 (2):351-360 - 16.
Hargreave F, Pepys J, Holford-Strevens V. Bagassosis. The Lancet. 1968; 291 (7543):619-620 - 17.
Goodfellow M, Kempfer P, Busse HJ, Trujillo ME, Suzuki K-I, Ludwig W, et al. Bergey's Manual of Systematic Bacteriology: Volume Five The Actinobacteria, Part A. New York, NY: Springer New York; 2012 - 18.
Schäfer J, Kämpfer P, Jäckel U. Detection of Saccharopolyspora rectivirgula by quantitative real-time PCR. Annals of Occupational Hygiene. 2011; 55 (6):612-619 - 19.
Cano-Jiménez E, Acuña A, Botana MI, Hermida T, González MG, Leiro V, et al. Farmer's lung disease. A review. Archivos de Bronconeumología (English Edition). 2016; 52 (6):321-328 - 20.
Bourke S, Dalphin J, Boyd G, McSharry C, Baldwin C, Calvert J. Hypersensitivity pneumonitis: Current concepts. European Respiratory Journal. 2001; 18 (Suppl. 32):81s-92s - 21.
Ramazzini B. Diseases of Workers. New York: Hafner Pub. Co.; 1964 - 22.
Campbell JM. Acute symptoms following work with Hay. The British Medical Journal. 1932; 2 (3755):1143-1144 - 23.
Jose J, Craig TJ. Hypersensitivity pneumonitis. Allergy and Asthma: Springer; 2016. pp. 311-331 - 24.
Churg A. Hypersensitivity pneumonitis: New concepts and classifications. Modern Pathology. 2022; 35 :15-27 - 25.
Dickie HA, Rankin J. Farmer's lung: An acute granulomatous interstitial pneumonitis occurring in agricultural workers. Journal of the American Medical Association. 1958; 167 (9):1069-1076 - 26.
Barnes H, Jones K, Blanc P. The hidden history of hypersensitivity pneumonitis. European Respiratory Journal. 20 Jan 2022; 59 (1):2100252 - 27.
Barnes H, Troy L, Lee CT, Sperling A, Strek M, Glaspole I. Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment. Allergy. 2022; 77 (2):442-453 - 28.
Nance S, Cross R, Yi AK, Fitzpatrick EA. IFN-γ production by innate immune cells is sufficient for development of hypersensitivity pneumonitis. European Journal of Immunology. 2005; 35 (6):1928-1938 - 29.
Simonian PL, Roark CL, Born WK, O'Brien RL, Fontenot AP. γδ T cells and Th17 cytokines in hypersensitivity pneumonitis and lung fibrosis. Translational Research. 2009; 154 (5):222-227 - 30.
Soumagne T, Chardon M-L, Dournes G, Laurent L, Degano B, Laurent F, et al. Emphysema in active farmer’s lung disease. PLoS One. 2017; 12 (6):e0178263 - 31.
Erkinjuntti-Pekkanen R, Rytkonen H, Kokkarinen JI, Tukiainen HO, Partanen K, Terho EO. Long-term risk of emphysema in patients with farmer's lung and matched control farmers. American journal of respiratory and critical care medicine. 1998; 158 (2):662-665 - 32.
Shah PL, Herth FJ, Lee YG, Criner GJ. Essentials of Clinical Pulmonology. Boca Raton: CRC Press; 2018 - 33.
Morell F, Ojanguren I, Cruz M-J. Diagnosis of occupational hypersensitivity pneumonitis. Current Opinion in Allergy and Clinical Immunology. 2019; 19 (2):105-110 - 34.
Kokkarinen J, Tukiainen H, Terho EO. Severe farmer's lung following a workplace challenge. Scandinavian Journal of Work, Environment & Health. 1992; 18 (5):327-328 - 35.
Koster MA, Thomson CC, Collins BF, Jenkins AR, Ruminjo JK, Raghu G. Diagnosis of hypersensitivity pneumonitis in adults, 2020 clinical practice guideline: Summary for clinicians. Annals of the American Thoracic Society. 2021; 18 (4):559-566 - 36.
Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: Insights in diagnosis and pathobiology. American Journal of Respiratory and Critical Care Medicine. 2012; 186 (4):314-324 - 37.
Myers JL. Hypersensitivity pneumonia: The role of lung biopsy in diagnosis and management. Modern Pathology. 2012; 25 (1):S58-S67 - 38.
Aronson KI, O’Beirne R, Martinez FJ, Safford MM. Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States. Respiratory Research. 2021; 22 (1):1-10 - 39.
Ranalli G, Grazia L, Roggeri A. The influence of hay-packing techniques on the presence of Saccharopolyspora rectivirgula. Journal of Applied Microbiology. 1999; 87 (3):359-365 - 40.
Roussel S, Reboux G, Dalphin JC, Laplante JJ, Piarroux R. Evaluation of salting as a hay preservative against farmer's lung disease agents. Annals Of Agricultural And Environmental Medicine. 2005; 12 (2):217-221 - 41.
Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer’s lung 1-3. The American Review of Respiratory Disease. 1992; 145 :3-5 - 42.
Cano-Jiménez E, Rubal D, de Llano LAP, Mengual N, Castro-Añón O, Méndez L, et al. Farmer's lung disease: Analysis of 75 cases. Medicina Clínica (English Edition). 2017; 149 (10):429-435 - 43.
Liu S, Chen D, Fu S, Ren Y, Wang L, Zhang Y, et al. Prevalence and risk factors for farmer’s lung in greenhouse farmers: An epidemiological study of 5,880 farmers from Northeast China. Cell Biochemistry and Biophysics. 2015; 71 (2):1051-1057 - 44.
Hoppin JA, Umbach DM, Long S, Rinsky JL, Henneberger PK, Salo PM, et al. Respiratory disease in United States farmers. Occupational and Environmental Medicine. 2014; 71 (7):484-491 - 45.
Hoppin JA, Umbach DM, Kullman GJ, Henneberger PK, London SJ, Alavanja MC, et al. Pesticides and other agricultural factors associated with self-reported farmer’s lung among farm residents in the agricultural health study. Occupational and Environmental Medicine. 2007; 64 (5):334-341 - 46.
Cormier Y, Israel-Assayag E, Fournier M, Tremblay GM. Modulation of experimental hypersensitivity pneumonitis by Sendai virus. The Journal of Laboratory and Clinical Medicine. 1993; 121 (5):683-688 - 47.
Cormier Y, Tremblay G, Fournier M, Israël-Assayag E. Long-term viral enhancement of lung response to Saccharopolyspora rectivirgula. American Journal of Respiratory and Critical Care Medicine. 1994; 149 (2):490-494 - 48.
Costabel U, Miyazaki Y, Pardo A, Koschel D, Bonella F, Spagnolo P, et al. Hypersensitivity pneumonitis. Nature Reviews Disease Primers. 2020; 6 (1):65 - 49.
Millerick-May M, Mulks M, Gerlach J, Flaherty K, Schmidt S, Martinez F, et al. Hypersensitivity pneumonitis and antigen identification–an alternate approach. Respiratory Medicine. 2016; 112 :97-105 - 50.
Kotimaa MH, Husman KH, Terho EO, Mustonen MH. Airborne molds and actinomycetes in the work environment of farmer's lung patients in Finland. Scandinavian Journal of Work, Environment & Health. 1984; 10 (2):115-119 - 51.
Marx JJ Jr, Kettrick-Marx MA, Mitchell PD, Flaherty DK. Correlation of exposure to various respiratory pathogens with farmer's lung disease. Journal of Allergy and Clinical Immunology. 1977; 60 (3):169-173 - 52.
Dakhama A, Hegele RG, Laflamme G, Israel-Assayag E, Cormier Y. Common respiratory viruses in lower airways of patients with acute hypersensitivity pneumonitis. American Journal of Respiratory and Critical Care Medicine. 1999; 159 (4):1316-1322 - 53.
Cormier Y, Samson N, Isräel-Assayag E. Viral infection enhances the response to Saccharopolyspora rectivirgula in mice prechallenged with this farmer's lung antigen. Lung. 1996; 174 (6):399-407 - 54.
Sordillo JE, Hoffman EB, Celedón JC, Litonjua AA, Milton DK, Gold DR. Multiple microbial exposures in the home may protect against asthma or allergy in childhood. Clinical & Experimental Allergy. 2010; 40 (6):902-910 - 55.
Perkin MR, Strachan DP. Which aspects of the farming lifestyle explain the inverse association with childhood allergy? Journal of Allergy and Clinical Immunology. 2006; 117 (6):1374-1381 - 56.
Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin JC, Riedler J, et al. Farm exposure and time trends in early childhood may influence DNA methylation in genes related to asthma and allergy. Allergy. 2013; 68 (3):355-364 - 57.
Murphy K. In: Weaver C, editor. Janeway’s Immunobiology. 9th ed. New York, NY: Garland Science/Taylor & Francis Group, LLC; 2017 - 58.
Venkatesh P, Wild L. Hypersensitivity pneumonitis in children. Pediatric Drugs. 2005; 7 (4):235-244 - 59.
Russell SL, Gold MJ, Reynolds LA, Willing BP, Dimitriu P, Thorson L, et al. Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases. Journal of Allergy and Clinical Immunology. 2015; 135 (1):100-9. e5 - 60.
Vasakova M, Selman M, Morell F, Sterclova M, Molina-Molina M, Raghu G. Hypersensitivity pneumonitis: Current concepts of pathogenesis and potential targets for treatment. American Journal of Respiratory and Critical Care Medicine. 2019; 200 (3):301-308 - 61.
Schaaf BM, Seitzer U, Pravica V, Aries SP, Zabel P. Tumor necrosis factor-α− 308 promoter gene polymorphism and increased tumor necrosis factor serum bioactivity in farmer's lung patients. American Journal of Respiratory and Critical Care Medicine. 2001; 163 (2):379-382 - 62.
Mahto H, Tripathy R, Meher BR, Prusty BK, Sharma M, Deogharia D, et al. TNF-α promoter polymorphisms (G-238A and G-308A) are associated with susceptibility to systemic lupus erythematosus (SLE) and P. falciparum malaria: A study in malaria endemic area. Scientific Reports. 2019; 9 (1):1-11 - 63.
Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, et al. Major histocompatibility complex (MHC) class I and MHC class II proteins: Conformational plasticity in antigen presentation. Frontiers in Immunology. 2017; 8 :292 - 64.
Aquino-Galvez A, Camarena Á, Montaño M, Juarez A, Zamora AC, González-Avila G, et al. Transporter associated with antigen processing (TAP) 1 gene polymorphisms in patients with hypersensitivity pneumonitis. Experimental and Molecular Pathology. 2008; 84 (2):173-177 - 65.
Falfán-Valencia R, Camarena Á, Pineda CL, Montaño M, Juárez A, Buendía-Roldán I, et al. Genetic susceptibility to multicase hypersensitivity pneumonitis is associated with the TNF-238 GG genotype of the promoter region and HLA-DRB1* 04 bearing HLA haplotypes. Respiratory Medicine. 2014; 108 (1):211-217 - 66.
Bernhard W. Lung surfactant: Function and composition in the context of development and respiratory physiology. Annals of Anatomy-Anatomischer Anzeiger. 2016; 208 :146-150 - 67.
Chroneos Z, Sever-Chroneos Z, Shepherd V. Pulmonary surfactant: An immunological perspective. Cellular Physiology and Biochemistry. 2010; 25 (1):13-26 - 68.
Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Frontiers in Immunology. 2012; 3 :131 - 69.
Pantelidis P, Veeraraghavan S, Du Bois RM. Surfactant gene polymorphisms and interstitial lung diseases. Respiratory Research. 2001; 3 (1):1-7 - 70.
Cormier Y, Israel-Assayag E, Desmeules M, Lesur O. Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein a levels in subjects with farmer's lung. Thorax. 1996; 51 (12):1210-1215 - 71.
Hamm H, Lührs J, y Rotaeche JG, Costabel U, Fabel H, Bartsch W. Elevated surfactant protein a in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest. 1994; 106 (6):1766-1770 - 72.
Okamoto T, Fujii M, Furusawa H, Tsuchiya K, Miyazaki Y, Inase N. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respiratory Medicine. 2015; 109 (12):1576-1581 - 73.
Israël-Assayag E, Cormier Y. Surfactant modifies the lymphoproliferative activity of macrophages in hypersensitivity pneumonitis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 1997; 273 (6):L1258-L1L64 - 74.
Simonian PL, Roark CL, Wehrmann F, Lanham AK, del Valle FD, Born WK, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. The Journal of Immunology. 2009; 182 (1):657-665 - 75.
Greenberger PA. Hypersensitivity pneumonitis: A fibrosing alveolitis produced by inhalation of diverse antigens. Journal of Allergy and Clinical Immunology. 2019; 143 (4):1295-1301 - 76.
Andrews K, Ghosh MC, Schwingshackl A, Rapalo G, Luellen C, Waters CM, et al. Chronic hypersensitivity pneumonitis caused by Saccharopolyspora rectivirgula is not associated with a switch to a Th2 response. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2016; 310 (5):L393-L402 - 77.
Costabel U. The alveolitis of hypersensitivity pneumonitis. European Respiratory Journal. 1988; 1 (1):5-9 - 78.
Cottin V. Interstitial lung disease. European Respiratory Review. 2013; 22 (127):26-32 - 79.
Schuyler M, Gott K, Shopp G, Crooks L. CD3+ and CD4+ cells adoptively transfer experimental hypersensitivity pneumonitis. The American Review of Respiratory Disease. 1992; 146 (6):1582-1588 - 80.
Schuyler M, Crooks L. Experimental hypersensitivity pneumonitis in Guinea pigs. The American Review of Respiratory Disease. 1989; 139 :996-1002 - 81.
Gudmundsson G, Hunninghake GW. Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. The Journal of Clinical Investigation. 1997; 99 (10):2386-2390 - 82.
Gudmundsson G, Bosch A, Davidson BL, Berg DJ, Hunninghake GW. Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. American Journal of Respiratory Cell and Molecular Biology. 1998; 19 (5):812-818 - 83.
Gudmundsson G, Monick MM, Hunninghake GW. IL-12 modulates expression of hypersensitivity pneumonitis. The Journal of Immunology. 1998; 161 (2):991-999 - 84.
Nance SC, Yi AK, Re FC, Fitzpatrick EA. MyD88 is necessary for neutrophil recruitment in hypersensitivity pneumonitis. Journal of Leukocyte Biology. 2008; 83 (5):1207-1217 - 85.
Joshi AD, Fong DJ, Oak SR, Trujillo G, Flaherty KR, Martinez FJ, et al. Interleukin-17–mediated immunopathogenesis in experimental hypersensitivity pneumonitis. American Journal of Respiratory and Critical Care Medicine. 2009; 179 (8):705-716 - 86.
Matsuno Y, Ishii Y, Yoh K, Morishima Y, Haraguchi N, Kikuchi N, et al. Overexpression of GATA-3 protects against the development of hypersensitivity pneumonitis. American Journal of Respiratory and Critical Care Medicine. 2007; 176 (10):1015-1025 - 87.
de Oliviera NL, Massari P, Wetzler LM. The role of TLR2 in infection and immunity. Frontiers in Immunology. 2012; 3 :79 - 88.
Christmas P. Toll-like receptors: Sensors that detect infection. Nature Education. 2010; 3 (9):85 - 89.
Ishii KJ, Akira S. 3 - innate immunity. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, editors. Clinical Immunology. Third ed. Edinburgh: Mosby; 2008. pp. 39-51 - 90.
Lamphier MS, Sirois CM, Verma A, Golenbock DT, Latz E. TLR9 and the recognition of self and non-self nucleic acids. Annals of the New York Academy of Sciences. 2006; 1082 (1):31-43 - 91.
Andrews K, Abdelsamed H, Yi A-K, Miller MA, Fitzpatrick EA. TLR2 regulates neutrophil recruitment and cytokine production with minor contributions from TLR9 during hypersensitivity pneumonitis. PLoS One. 2013; 8 (8):e73143 - 92.
Lentini G, Famà A, Biondo C, Mohammadi N, Galbo R, Mancuso G, et al. Neutrophils enhance their own influx to sites of bacterial infection via endosomal TLR-dependent Cxcl2 production. The Journal of Immunology. 2020; 204 (3):660-670 - 93.
Sabroe I, Prince LR, Jones EC, Horsburgh MJ, Foster SJ, Vogel SN, et al. Selective roles for toll-like receptor (TLR) 2 and TLR4 in the regulation of neutrophil activation and life span. The Journal of Immunology. 2003; 170 (10):5268-5275 - 94.
Kim Y-I, Park J-E, Brand DD, Fitzpatrick EA, Yi A-K. Protein kinase D1 is essential for the proinflammatory response induced by hypersensitivity pneumonitis-causing thermophilic actinomycetes Saccharopolyspora rectivirgula. The Journal of Immunology. 2010; 184 (6):3145-3156 - 95.
Marcer G, Simioni L, Saia B, Saladino G, Gemignani C, Mastrangelo G. Study of immunological parameters in farmer's lung. Clinical Allergy. 1983; 13 (5):443-449 - 96.
Mundt C, Becker W-M, Schlaak M. Farmer's lung: Patients’ IgG2 antibodies specifically recognize Saccharopolyspora rectivirgula proteins and carbohydrate structures. Journal of Allergy and Clinical Immunology. 1996; 98 (2):441-450 - 97.
Abdelsamed HA, Desai M, Nance SC, Fitzpatrick EA. T-bet controls severity of hypersensitivity pneumonitis. Journal of Inflammation. 2011; 8 (1):1-11 - 98.
Yamasaki H, Ando M, Brazer W, Center DM, Cruikshank WW. Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. The Journal of Immunology. 1999; 163 (6):3516-3523 - 99.
Flynn JL, Chan J, Lin P. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunology. 2011; 4 (3):271-278 - 100.
Pagán AJ, Ramakrishnan L. The formation and function of granulomas. Annual Review of Immunology. 2018; 36 :639-665 - 101.
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology. 2003; 3 (2):133-146 - 102.
Elmore JP, Carter C, Redko A, Koylass N, Bennett A, Mead M et al. Itk independent development of Th17 responses during Hypersensitivity pneumonitis”. Communications Biology. 2022; 5 :162. DOI: 10.1038/s42003-022-03109-1 - 103.
Marwaha A, Leung N, McMurchy AN, Levings M. TH17 cells in autoimmunity and immunodeficiency: Protective or pathogenic? Frontiers in Immunology. 2012; 3 :129 - 104.
Wu X, Tian J, Wang S. Insight into non-pathogenic Th17 cells in autoimmune diseases. Frontiers in Immunology. 2018; 9 :1112 - 105.
Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. American Journal of Respiratory and Critical Care Medicine. 2006; 173 (2):188-198 - 106.
Montaldo E, Juelke K, Romagnani C. Group 3 innate lymphoid cells (ILC3s): Origin, differentiation, and plasticity in humans and mice. European Journal of Immunology. 2015; 45 (8):2171-2182 - 107.
Papotto PH, Ribot JC, Silva-Santos B. IL-17+ γδ T cells as kick-starters of inflammation. Nature Immunology. 2017; 18 (6):604-611 - 108.
Yu J-S, Hamada M, Ohtsuka S, Yoh K, Takahashi S, Miaw S-C. Differentiation of IL-17-producing invariant natural killer T cells requires expression of the transcription factor c-Maf. Frontiers in Immunology. 2017; 8 :1399 - 109.
Hu S, He W, Du X, Yang J, Wen Q , Zhong X-P, et al. IL-17 production of neutrophils enhances antibacteria ability but promotes arthritis development during mycobacterium tuberculosis infection. eBioMedicine. 2017; 23 :88-99 - 110.
Hasan SA, Eksteen B, Reid D, Paine HV, Alansary A, Johannson K, et al. Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis. Journal of Allergy and Clinical Immunology. 2013; 131 (6):1663-73.e5 - 111.
Żabińska M, Krajewska M, Kościelska-Kasprzak K, Jakuszko K, Bartoszek D, Myszka M, et al. CD4+ CD25+ CD127− and CD4+ CD25+ Foxp3+ regulatory T cell subsets in mediating autoimmune reactivity in systemic lupus erythematosus patients. Archivum Immunologiae et Therapiae Experimentalis. 2016; 64 (5):399-407 - 112.
Girard M, Israel-Assayag E, Cormier Y. Impaired function of regulatory T-cells in hypersensitivity pneumonitis. European Respiratory Journal. 2011; 37 (3):632-639 - 113.
Behbehani GK. Immunophenotyping by Mass Cytometry. Immunophenotyping: Springer; 2019. pp. 31-51 - 114.
Holmberg-Thyden S, Grønbæk K, Gang AO, El Fassi D, Hadrup SR. A user’s guide to multicolor flow cytometry panels for comprehensive immune profiling. Analytical Biochemistry. 2021; 15 ;627:114210 - 115.
Barnes CS, Alexis NE, Bernstein JA, Cohn JR, Demain JG, Horner E, et al. Climate change and our environment: The effect on respiratory and allergic disease. The Journal of Allergy and Clinical Immunology: In Practice. 2013; 1 (2):137-141 - 116.
Barnes CS. Impact of climate change on pollen and respiratory disease. Current allergy and asthma reports. 2018; 18 (11):1-11 - 117.
D'amato G, Pawankar R, Vitale C, Lanza M, Molino A, Stanziola A, et al. Climate change and air pollution: Effects on respiratory allergy. Allergy, Asthma & Immunology Research. 2016; 8 (5):391-395 - 118.
Casadevall A. Climate change brings the specter of new infectious diseases. The Journal of Clinical Investigation. 2020; 130 (2):553-555